Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q4 2019

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q4 2019” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q4 2019. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharma Intelligence Center deals database and primary and secondary research.

Scope

Analysis of the market trends for the pharmaceutical industry in the global arena.

Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

Analysis of partnership and licensing deals based on clinical stage of development of products.

Summary of the pharmaceutical deals globally in the five quarters.

Information on the top deals happened in the pharmaceutical industry.

Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

Enhance your decision making capability in a more rapid and time sensitive manner.

Find out the major deal performing segments for investments in your industry.

Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

Identify companies that are aggressively looking to raise capital in the market

Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

Identify growth segments and opportunities in each region within the industry.

Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1. Table of Contents

1. Table of Contents 2

1.1. List of Tables 5

1.2. List of Figures 7

2. Deals in Pharmaceutical & Healthcare Industry Decreased in Q4 2019 9

2.1. Pharmaceuticals & Healthcare, Deal Summary, Q4 2019 9

3. Pharmaceuticals & Healthcare, Global, Deal Summary, Q4 2019 13

3.1. Pharmaceuticals & Healthcare, Global, Deals Analysis, Q4 2019 13

3.2. Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q4 2019 15

3.3. Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q4 2019 16

3.4. Pharmaceuticals & Healthcare, Global, Top Deals, Q4 2019 17

3.4.1. AbbVie Raises USD30 Billion in Private Placement of Notes 17

3.4.2. Novartis Acquires Medicines Co 17

3.4.3. Stryker to Acquire Wright Medical 18

3.4.4. Mitsubishi Chemical to Acquire Remaining

46.31% Stake in Mitsubishi Tanabe Pharma for USD4.52 Billion 19

3.4.5. Roche to Enter into Licensing Agreement with Sarepta Therapeutics 19

4. Pharmaceuticals & Healthcare, Global, Deals Summary, by Type 20

4.1. Pharmaceuticals & Healthcare, Global, M&A, Q4 2019 20

4.1.1. Top M&A Deals in Q4 2019 21

4.1.3. Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q4 2018 – Q4 2019 22

4.2. Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q4 2019 23

4.2.1. Top Initial Public Offerings in Q4 2019 24

4.2.2. Top Secondary Offerings in Q4 2019 24

4.2.3. Top PIPE Deals in Q4 2019 25

4.2.4. Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q4 2018 – Q4 2019 26

4.3. Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q4 2019 27

4.3.1. Top Venture Financing Deals in Q4 2019 28

4.3.3. Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q4 2019 29

4.3.4. Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q4 2019 31

4.3.6. Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q4 2018 – Q4 2019 32

4.3.7. Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Q4 2018 – Q4 2019 33

4.3.8. Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q4 2018 – Q4 2019 34

4.5. Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q4 2019 35

4.5.1. Top Private Equity Deals in Q4 2019 36

4.5.2. Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q4 2018 – Q4 2019 37

5. Pharmaceuticals & Healthcare, Global, Partnership Deals, Q4 2019 38

5.1. Pharmaceuticals & Healthcare, Global, Partnership Deals, Q4 2019 38

5.2. Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q4 2018 – Q4 2019 39

5.3. Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2019 41

5.3.1. Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q4 2019 42

5.3.2. Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q4 2019 42

5.3.3. Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q4 2019 43

5.5. Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2018 – Q4 2019 44

5.6. Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q4 2018 – Q4 2019 46

5.7. Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q4 2018 – Q4 2019 47

5.8. Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2018 – Q4 2019 48

6. Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q4 2019 50

6.1. Pharmaceutical & Healthcare, Global, Licensing Agreements, Q4 2019 50

6.2. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q4 2018 – Q4 2019 51

6.2.1. Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q4 2019 52

6.2.2. Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q4 2019 52

6.2.3. Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q4 2019 53

6.3. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q4 2018 – Q4 2019 54

6.4. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q4 2018 – Q4 2019 55

6.5. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q4 2018 – Q4 2019 57

6.6. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q4 2018 – Q4 2019 58

6.7. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q4 2018 – Q4 2019 60

7. Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 62

7.1. Pharmaceuticals & Healthcare, Global, Oncology Deals, Q4 2019 62

7.1.1. Oncology – Deals of the Quarter 63

7.2. Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q4 2019 65

7.2.1. Central Nervous System – Deals of the Quarter 66

7.3. Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q4 2019 69

7.3.1. Infectious Disease – Deals of the Quarter 70

7.4. Pharmaceuticals & Healthcare, Global, Immunology Deals, Q4 2019 71

7.4.1. Immunology – Deals of the Quarter 72

7.5. Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q4 2019 74

7.5.1. Metabolic Disorders – Deals of the Quarter 75

7.6. Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q4 2019 77

7.6.1. Cardiovascular – Deals of the Quarter 78

7.7. Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q4 2019 80

7.7.1. Gastrointestinal – Deals of the Quarter 81

7.8. Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q4 2019 83

7.8.1. Dermatology – Deals of the Quarter 84

7.9. Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q4 2019 86

7.9.1. Respiratory – Deals of the Quarter 87

7.10. Pharmaceuticals & Healthcare, Global, Ophthalmology Deals, Q4 2019 89

7.10.1. Ophthalmology – Deals of the Quarter 90

8. Deal Summary by Geography 92

8.1. Pharmaceuticals & Healthcare, North America Region, Deals, Q4 2019 92

8.1.1. North America – Deals of the Quarter 93

8.2. Pharmaceuticals & Healthcare, Europe Region, Deals, Q4 2019 96

8.2.1. Europe – Deals of the Quarter 97

8.3. Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q4 2019 100

8.3.1. Asia-Pacific – Deals of the Quarter 101

8.4. Pharmaceuticals & Healthcare, Rest of the World, Deals, Q4 2019 102

8.4.1. Rest of the World – Deals of the Quarter 103

9. Pharmaceuticals & Healthcare, Global, Top Advisors 104

9.1. Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Q4 2018 – Q4 2019 104

9.2. Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Q4 2018 – Q4 2019 106

10. Further Information 108

10.1. Methodology 108

10.2. About GlobalData 108

10.3. Contact Us 109

10.4. Disclosure information 109

10.5. Disclaimer 109

List of Tables

1.1. List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deal Summary, Number of Deals and Deal Values (US$m), Q4 2018 – Q4 2019 14

Table 2: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), Q4 2019 16

Table 3: Pharmaceuticals & Healthcare, Global, Top Deals, Q4 2019 17

Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2018 – Q4 2019 21

Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, Q4 2019 21

Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, , Q4 2018 – Q4 2019 22

Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$m), Q4 2018 – Q4 2019 24

Table 8: Pharmaceuticals & Healthcare, Global, Top Initial Public Offering Deals, Q4 2019 24

Table 9: Pharmaceuticals & Healthcare, Global, Top Secondary Offering Deals, Q4 2019 24

Table 10: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, Q4 2019 25

Table 11: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$m), Q4 2018 – Q4 2019 26

Table 12: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2018 – Q4 2019 28

Table 13: Pharmaceuticals & Healthcare, Global, Top Venture Capital Deals, Q4 2019 28

Table 14: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), Q4 2019 31

Table 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q4 2018 – Q4 2019 32

Table 16: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q4 2018 – Q4 2019 33

Table 17: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q4 2018 – Q4 2019 34

Table 18: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2018 – Q4 2019 35

Table 19: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, Q4 2019 36

Table 20: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q4 2018 – Q4 2019 37

Table 21: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q4 2018 – Q4 2019 39

Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q4 2018 – Q4 2019 40

Table 23: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q4 2018 – Q4 2019 41

Table 24: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payments and Deal Values (US$ m), Q4 2019 42

Table 25: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q4 2019 42

Table 26: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q4 2019 43

Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q4 2018 – Q4 2019 45

Table 28: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q4 2018 – Q4 2019 47

Table 29: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (US$ m), Q4 2018 – Q4 2019 49

Table 30: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deal Summary, Number of Deals and Deal Values (US$ m), Q4 2018 – Q4 2019 50

Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront & Milestone Payments and Deal Values (US$ m), Q4 2018 – Q4 2019 51

Table 32: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Deal Values, Q4 2019 52

Table 33: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Upfront Payment, Q4 2019 52

Table 34: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Milestone Payment, Q4 2019 53

Table 35: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q4 2018 – Q4 2019 54

Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment (US$ m), Q4 2018 – Q4 2019 56

Table 37: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Q4 2018 – Q4 2019 59

Table 38: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment and Deal Values (US$ m), Q4 2018 – Q4 2019 61

Table 39: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2018 – Q4 2019 63

Table 40: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2018 – Q4 2019 66

Table 41: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2018 – Q4 2019 70

Table 42: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2018 – Q4 2019 72

Table 43: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2018 – Q4 2019 75

Table 44: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2018 – Q4 2019 78

Table 45: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2018 – Q4 2019 81

Table 46: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2018 – Q4 2019 84

Table 47: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2018 – Q4 2019 87

Table 48: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2018 – Q4 2019 90

Table 49: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2018 – Q4 2019 93

Table 50: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2018 – Q4 2019 97

Table 51: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2018 – Q4 2019 101

Table 52: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2018 – Q4 2019 103

Table 53: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q4 2018 – Q4 2019 105

Table 54: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q4 2018 – Q4 2019 107

List of Figures

1.2. List of Figures

Figure 1: Pharmaceuticals & Healthcare, Number Of Deals, Q4 2018 – Q4 2019 10

Figure 2: Pharmaceuticals & Healthcare, Licensing Deals By Payment Mode, Q4 2018 – Q4 2019 11

Figure 3: Pharmaceuticals & Healthcare, Number Of Deals by Markets, Q4 2019 11

Figure 4: Pharmaceuticals & Healthcare, Number Of Deals by Region, Q4 2019 12

Figure 5: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$m), Q4 2018 – Q4 2019 13

Figure 6: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), Q4 2019 15

Figure 7: Pharmaceuticals & Healthcare, Global, Deal Values (%), Q4 2019 16

Figure 8: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$m), Q4 2018 – Q4 2019 20

Figure 9: Pharmaceuticals & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (US$m), by Therapy Area, Q4 2018 – Q4 2019 22

Figure 10: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q4 2018 – Q4 2019 23

Figure 11: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$m), Q4 2018 – Q4 2019 26

Figure 12: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q4 2018 – Q4 2019 27

Figure 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%), Q4 2019 29

Figure 14: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Deal Values (%), Q4 2019 31

Figure 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q4 2018 – Q4 2019 32

Figure 16: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q4 2018 – Q4 2019 33

Figure 17: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q4 2018 – Q4 2019 35

Figure 18: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q4 2018 – Q4 2019 37

Figure 19: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q4 2018 – Q4 2019 38

Figure 20: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q4 2018 – Q4 2019 39

Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payment and Deal Values (US$ m), Q4 2018 – Q4 2019 41

Figure 22: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q4 2018 – Q4 2019 44

Figure 23: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q4 2018 – Q4 2019 46

Figure 24: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q4 2018 – Q4 2019 47

Figure 25: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payment and Deal Values (US$ m), Q4 2018 – Q4 2019 48

Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q4 2018 – Q4 2019 50

Figure 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2018 – Q4 2019 51

Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q4 2018 – Q4 2019 54

Figure 29: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront & Milestone Payments and Deal Values (US$ m), Q4 2018 – Q4 2019 55

Figure 30: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals, Q4 2018 – Q4 2019 57

Figure 31: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Deal Values (US$ m), Q4 2018 – Q4 2019 58

Figure 32: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2018 – Q4 2019 60

Figure 33: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q4 2018 – Q4 2019 62

Figure 34: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), Q4 2018 – Q4 2019 65

Figure 35: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Values (US$ m), Q4 2018 – Q4 2019 69

Figure 36: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q4 2018 – Q4 2019 71

Figure 37: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q4 2018 – Q4 2019 74

Figure 38: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q4 2018 – Q4 2019 77

Figure 39: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2018 – Q4 2019 80

Figure 40: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2018 – Q4 2019 83

Figure 41: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2018 – Q4 2019 86

Figure 42: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2018 – Q4 2019 89

Figure 43: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), Q4 2018 – Q4 2019 92

Figure 44: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), Q4 2018 – Q4 2019 96

Figure 45: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), Q4 2018 – Q4 2019 100

Figure 46: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), Q4 2018 – Q4 2019 102

Figure 47: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q4 2018 – Q4 2019 104

Figure 48: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q4 2018 – Q4 2019 106

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2745

Join our mailing list

Saved reports